Search
for
Sort by
Research 30 of 1000+
- IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
- When bugs and drugs conspire: driving acneiform skin toxicity
- Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
- Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Management of Dermatologic Toxicities
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- Targeted Treatments of Non-Small Cell Lung Cancer (NSCLC): Skin Toxicity
- Drug-Induced Skin, Nail and Hair Disorders
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Sorafenib-induced Facial Acneiform Eruption
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Prophylaxis and Management of Skin Toxicities
- Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation
- Dermatologic Reactions to Targeted Therapy
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Cetuximab-induced hypertrichosis of the scalp and eyelashes
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Dermatologic Adverse Events from Cancer Treatments